Agios Pharmaceuticals (FRA:8AP) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8AP Agios Pharmaceuticals Inc FRA:8AP
46 GF Score
Price €34.60
GF Value €73.78
! 5 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:8AP
46GF Score
Agios Pharmaceuticals Inc FRA:8AP
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €34.60 is trading 53.1% below its estimated GF Value™ of €73.78.

Key valuation signals for FRA:8AP:

  • Interest Received:
  • GF Value™: €73.78 vs. price of €34.60 (53.1% below fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
46GF Score

Get the complete analysis for FRA:8AP

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.60
Price
€73.78
GF Value